Baird analyst Brian Skorney raised the firm’s price target on Alto Neuroscience (ANRO) to $41 from $22 and keeps an Outperform rating on the shares. The firm updated its model ahead of multiple catalysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile
- Alto Neuroscience price target raised to $22 from $13 at Wedbush
- Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating
- Alto Neuroscience Secures $120 Million Private Placement Financing
- Alto Neuroscience to sell 2.9M shares at $20.00 in private placement